Business Context and Reporting Period
This Form 8-K filing by Illumina, Inc. (ILMN) reports a material legal event occurring on May 6, 2022. The report addresses a jury verdict in the U.S. District Court for the District of Delaware regarding patent infringement litigation with Complete Genomics, Inc. (CGI).
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to the legal judgment:
- Legal Damages Awarded: Approximately $334 million in past damages awarded to Complete Genomics, Inc.
Material Changes and Legal Developments
The primary material change is the adverse jury verdict against Illumina:
- Infringement Finding: The jury found Illumina willfully infringed U.S. Patent Nos. 9,222,132 and 10,662,473 owned by CGI.
- Patent Invalidations: The jury invalidated three Illumina patents: U.S. Patent Nos. 9,217,178; 9,303,290; and 9,970,055.
- Future Obligations: If appeals fail, Illumina may face interest on the judgment and an ongoing royalty rate to be determined by the court until the patents expire in January 2029.
Management Commentary, Risks, and Outlook
Management disputes the verdict and intends to vigorously defend the action through all appropriate appeals. Regarding potential injunctions, management states there is no reasonable basis for the court to grant one. The filing highlights the risk of future royalty payments and interest accrual if the appeal is unsuccessful.
Key Facts for Investor Verification
- Verify the status of Illumina's appeal against the $334 million damages award.
- Monitor court proceedings for the determination of any ongoing royalty rates.
- Assess the impact of the invalidated patents on Illumina's intellectual property portfolio and future litigation strategy.
- Review subsequent filings for updates on the potential interest accrual on the judgment.